1411 - Outcomes, inequities, and access to front-line preferred therapies for chronic lymphocytic leukemia in the United States: a real-world evidence study

Primary Author / Presenter(s)

Paul J J. Hampel, MD

Assistant Professor of Medicine, Assistant Professor of Oncology
Department of Medicine, Mayo Clinic
Rochester, Minnesota, United States
JR

Joanna Rhodes, MD

Rutgers Cancer Institute of New Jersey, New Jersey, United States
XW

Xiaoliang Wang, PhD, MPH

BeOne Medicines Ltd
San Carlos, California, United States
QF

Qianhong Fu, MS

BeOne Medicines Ltd
San Carlos, California, United States
DZ

Danni Zhao, PhD, MScGH

Flatiron Health, New York, NY, USA
New York, New York, United States
SK

Smriti Karwa, MPH

Flatiron Health, New York, NY, USA
New York, New York, United States
TM

Taavy A Miller, PhD

Flatiron Health, New York, NY, USA
New York, New York, United States
OM

Olive Mbah, PhD, MHS

Flatiron Health, New York, NY, USA
New York, New York, United States
AS

Ahmed Sawas, MD

Flatiron Health, New York, NY, USA
New York, New York, United States
BW

Benji Wagner, MS

Flatiron Health, New York, NY, USA
New York, New York, United States
RM

Rachel Myers, MPH

Flatiron Health, New York, NY, USA
New York, New York, United States
Dv

Derrick van Beuge, PharmD

BeOne Medicines Ltd
San Carlos, California, United States
GM

Gregory A Maglinte, PhD, MPH

BeOne Medicines Ltd
San Carlos, California, United States
ES

Erlene K Seymour, MD

BeOne Medicines Ltd
San Carlos, California, United States
JB

Jacqueline C. Barrientos, MD, MS

Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States